This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT05295940 |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 148 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity; Healthy |
| Interventions | LY3841136; Placebo |
| Start | Mar 30, 2022 |
| Primary completion | Jan 25, 2024 |
| Study completion | Jan 25, 2024 |
| Results posted | Not yet |
| Registry last updated | Apr 1, 2024 |
Compounds on this site that cite this trial
What the registry says the trial is about
The main purpose of this study is to evaluate the safety and tolerability of LY3841136 in healthy and overweight participants. Blood tests will be performed to check how much LY3841136 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and may last up to 14 and 28 weeks for each participant and may include 7 and 19 visits in parts A and B, respectively.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Predose up to 14 weeks (Part A) & 28 weeks (Part B) |
3 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
